FY24 EBITDA margin target of 18%+ (ex-Revlimid)
Management targets 18%+ EBITDA margin for FY24, excluding Revlimid contribution, supported by operating leverage and export benefit normalization.
AUROPHARMA / guidance tracker
Keep management guidance in view.
Aurobindo Pharma · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
margins
Eugia global revenue target of $500M+ for FY24
Eugia aims to achieve $500M+ global revenue in FY24, up from $411M pro forma last year, excluding Revlimid.
PLI Pen-G facility completion by April 2024
PLI facilities and investments targeted to be completed before 1st April 2024, with full ramp-up expected by mid-FY25.
Biosimilar launches starting FY25
First oncology biosimilar launch in India expected this year, with multiple launches in regulated markets from FY25 onwards.
FY25 EBITDA margin target of 21%-22%
Management reiterated the internal EBITDA margin target of 21%-22% for FY25, with potential revision in Q2 call.
Europe revenue to exceed EUR 880 million for FY25
Europe formulations on track to achieve EUR 880 million+ for FY25, with potential to reach EUR 900 million.
Pen-G plant ramp-up from October 2024
Pen-G plant expected to ramp up significantly from October 2024, with 80% capacity utilization targeted by Q3.
China plant commercialization from Q3 FY25
China plant expected to start commercial production from Q3 FY25, with ramp-up from Q4 FY25.
FY26 EBITDA margin target of 20-21%
Management reiterated internal target margin range of 20-21% for FY26, supported by volume expansion and new site ramp-up.
China facility to break even at EBITDA by Q3 FY26
The China facility, with initial capacity of 2 billion+ units, is expected to break even at EBITDA level by Q3 FY26.
PNG plant to generate healthy EBITDA from Q3 FY26
The PNG plant resumed operations and is expected to generate healthy EBITDA from Q3 onwards as yields improve.
European business to cross €1B annual revenue by FY26 end
Management expects European formulations to exceed €1 billion in annual revenues by the end of FY26.
20%+ EBITDA margin target for FY24
Management targets full-year EBITDA margin above 20%, supported by gRevlimid launch and cost efficiencies.
Eugia Specialities global revenue of $560 million for FY24
On track to achieve $560 million globally for Eugia Specialities in FY24, driven by injectable growth.
Pen-G plant commissioning by Q4 FY24
Pen-G plant expected to be operational by end of Q4 FY24 or early Q1 FY25, with 15,000-ton capacity.
Biosimilar filings in Europe by January 2024
Three biosimilars (pegfilgrastim, filgrastim, trastuzumab) to be filed in Europe by end of January 2024.
FY25 EBITDA margin target of 21%-22%
Management reiterated internal target for full-year EBITDA margin, implying H2 margins will be higher than H1.
Penicillin G breakeven by Q4 FY25
Expect to achieve breakeven at the penicillin G facility by Q4 FY25, with positive contribution from FY26.
Global Eugia injectable sales ~$600M for FY25
Despite Q1/Q2 slowdown, management expects full-year injectable sales to be around $600M, with a possible 5% variance.
Biosimilar denosumab commercial in Europe by CY2026
Phase III recruitment completed; filing expected in 2025 with commercialization in Europe in 2026.
FY26 EBITDA margin target of 20-21%
Management reiterated confidence in achieving internal margin target of 20-21% for FY26, driven by operational leverage and cost efficiency.
Europe to exceed EUR 1 billion annual revenue by FY26 end
European business on track to comfortably surpass EUR 1 billion annual revenue milestone by end of FY26, driven by consistent growth across major markets.
China OSG facility EBITDA breakeven by Q3-Q4 FY26
The OSG facility in China is on track to deliver EBITDA breakeven by Q3-Q4 FY26, with European approval for 10 products and 3 local approvals.
Biosimilar denosumab EU submission in April 2026
Marketing authorization application for denosumab biosimilar to be submitted to EMA in April 2026; FDA submission expected in July quarter of 2026.
FY24 EBITDA margin target of 20%
Management reiterated confidence in achieving 20% EBITDA margin for FY24, supported by operational efficiencies and cost improvements.
Eugia Unit III production restart timeline
Non-aseptic lines expected to restart by end of February 2024; aseptic lines within 1-2 months; full production by end of FY24.
China plant revenue generation from Q1/Q2 FY25
The China oral solids plant has received cGMP approval and is expected to start generating revenue from Q1 or Q2 of FY2025.
Biosimilar Xolair revenue guidance of $120M-$180M by 2028
Management guided Xolair biosimilar revenue potential of $120M-$180M by 2028, assuming approvals in US and Europe.
FY25 EBITDA margin guidance of 21%-22%
Management reaffirmed achieving 21%-22% EBITDA margin for FY25, despite Q3 margin of 20.4%, citing stronger Q4 with increased transient sales and operational efficiencies.
China plant to contribute from FY26
The China OSD plant (2B units capacity) commercialized in November 2024, expected to ramp up and contribute to revenues in FY26, initially supplying Europe.
Dayton OSD plant commercialization in next fiscal
The US-based OSD plant at Dayton is expected to be commercialized in FY26, adding capacity for the US market.
Biosimilar launches in EU from July 2025
Following positive CHMP opinions, Filgrastim and Pegfilgrastim expected to launch in EU in Q2 FY26, with revenue bookings starting from that quarter.
EBITDA margin target of 20-21% for FY26
Management expects to achieve EBITDA margins on the higher side of 20-21% for FY2026, driven by Pen G ramp-up, injectable growth, and cost efficiencies.
Pen G production to exceed 10,000 metric tons annualized in next 12 months
Based on current production levels, the company expects to produce more than 10,000 metric tons on an annualized basis over the next 12 months.
Dayton facility to contribute significantly from FY27
The Dayton facility has transitioned to commercial phase and will begin contributing revenues significantly from FY2027 onwards.
Lannett acquisition expected to close in Q1 FY27
The acquisition is progressing well with FTC; expected to close in the first quarter of FY2027.
FY25 EBITDA margin target of 21%-22%
Management expects EBITDA margin to improve to 21%-22% in FY25, driven by operating leverage and ramp-up of new capacities.
Pen-G and 6-APA meaningful contribution from Q3 FY25
Pen-G and 6-APA facilities will start meaningful contribution from Q3 FY25, with full ramp-up expected by September 2024.
Eugia global revenue run rate of $150M per year
Eugia expects to maintain a global revenue run rate of $150 million per year, with US contributing $100-$110 million.
Biosimilar trastuzumab US filing within 3 months
Trastuzumab biosimilar to be filed with US FDA within the next 3 months, following a successful Type 4 pre-submission meeting.
High single-digit revenue growth in FY26 excluding transient products
Management expects revenue growth of 8-9% in FY26, excluding the contribution from transient products like Revlimid.
Maintain current EBITDA margins in FY26
The company internally aims to keep EBITDA margins at present levels (around 20.8%) for FY26.
China OSD plant to contribute revenues in FY26
The China plant, commercialized in FY25, is expected to contribute revenues in FY26 and turn breakeven or slightly positive.
US Dayton OSD plant commercialization in Q2 FY26
The US-based OSD plant at Dayton is expected to commence commercial manufacturing in Q2 of FY26.